Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 17 Mar 2022
COVID-19 vaccine weekly safety report (17 March 2022)
17 March 2022 - To 13 March 2022, the TGA has received 457 reports which have been assessed as likely to ...
Posted by Michael Wonder on 17 Mar 2022
PHARMAC widening access to rituximab and zoledronic acid
17 March 2022 - PHARMAC is widening access to two medicines, rituximab and zoledronic acid, estimated to benefit 1,750 New Zealanders ...
Posted by Michael Wonder on 16 Mar 2022
Rinvoq (upadacitinib) receives FDA approval for the treatment of adults with moderately to severely active ulcerative colitis
16 March 2022 - In clinical trials, Rinvoq (upadacitinib) achieved the primary endpoints of clinical remission (per modified Mayo Score) at ...
Posted by Michael Wonder on 16 Mar 2022
ICER publishes research protocol for assessing price increases of prescription drugs in California
16 March 2022 - Final assessment to be published on 13 October; drugs to be evaluated are those identified through California’s ...
Posted by Michael Wonder on 16 Mar 2022
Consequences of lack of funding for efforts to combat COVID-19 if Congress does not act
15 March 2022 - The U.S. has made tremendous progress in our fight against COVID-19. ...
Posted by Michael Wonder on 16 Mar 2022
FDA drafts guidance on genome editing, CAR T cell therapies
16 March 2022 - The U.S. FDA has issued two draft guidances addressing the development of human gene therapy products that ...
Posted by Michael Wonder on 16 Mar 2022
SK Bioscience submits a rolling review for COVID-19 vaccine 'GBP510' to British pharmaceutical authority
16 March 2022 - SK Bioscience announced today that it has submitted a rolling review document for rapid approval of ...
Posted by Michael Wonder on 16 Mar 2022
PHARMAC deal good news for New Zealanders
16 March 2022 - The Government is welcoming news the national drug-funding agency PHARMAC has secured an agreement for medicines ...
Posted by Michael Wonder on 16 Mar 2022
Pfizer and BioNTech submit for U.S. emergency use authorisation of an additional booster dose of their COVID-19 vaccine for older adults
15 March 2022 - Submission based on real-world safety and efficacy data from Israel. ...
Posted by Michael Wonder on 16 Mar 2022
Europe begins reviewing application for AstraZeneca COVID drug
15 March 2022 - Europe's drug regulator said on Tuesday it had begun reviewing AstraZeneca's application for antibody based COVID-19 therapy, ...
Posted by Michael Wonder on 16 Mar 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
16 March 2022 - NICE has published evidence-based recommendations on the use of dostarlimab (Jemperli) for the treatment of adults ...
Posted by Michael Wonder on 16 Mar 2022
Life-extending injection for blood cancer available on the NHS
15 March 2022 - A life-extending injection for a fatal form of blood cancer will be available to around 350 ...
Posted by Michael Wonder on 16 Mar 2022
Submission of oral edarvarone formulation, MT-1186 new drug application in Japan for ALS
14 March 2022 - Mitsubishi Tanabe Pharma announced that the company has submitted to the MHLW in Japan an application ...
Posted by Michael Wonder on 16 Mar 2022
PHARMAC to fund new treatments for lung and ovarian cancer
16 March 2022 - PHARMAC has confirmed today they are funding a bundle deal which will give New Zealanders more ...
Posted by Michael Wonder on 15 Mar 2022
New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
8 March 2022 - A new UK wide health technology assessment access forum has been developed by partners including the ...